SYNLAB AG
- WKN: A2TSL7
- ISIN: DE000A2TSL71
- Land: Deutschland
Nachricht vom 29.07.2021 | 10:01
SYNLAB: SYNLAB and AXA Partners enter a partnership to enhance safe travel this summer
DGAP-News: SYNLAB AG
/ Key word(s): Alliance
SYNLAB, Europe's leading medical diagnostic services provider, and AXA Partners enter a partnership to facilitate safe and easy travelling for customers and employees. AXA Partners is part of the AXA Group, a global leader in insurance and asset management, with more than 9,000 employees serving customers worldwide. Leveraging SYNLAB's broad laboratory network, AXA Partners' customers and employees are being offered comprehensive COVID-19 testing services in more than 10 European countries, including Spain, Portugal and France and covering around 900 testing centres. The partnership may be extended to include further countries. PCR tests are considered gold standard for COVID-19 testing, providing the highest possible sensitivity and specificity. A negative PCR test result ensures that customers and employees are not infected with SARS-CoV-2, which helps to protect their environment. In addition, it can also facilitate their on-/homeward journey and border crossing. Besides PCR testing, the partnership also includes antigen tests and self-administrated test kits, if country regulation permits. AXA Partners' customers and employees can find SYNLAB laboratories and sample collection points through AXA Partners' vetted medical network, whereby SYNLAB - as the preferred partner in testing for COVID-19 - is ranked first on search results. Mathieu Floreani, CEO of SYNLAB, says: "At a time when people around the world want to resume travel and different variants of the SARS-CoV-2 virus are spreading, testing remains crucial. We are pleased that AXA Partners has chosen SYNLAB as the preferred provider for testing. Together, we will make travel as safe as possible for their customers and employees." Julia d'Astorg, Chief International Medical Services Officer, AXA Partners: "We at AXA Partners continually strive to provide a best-in-class health services to our customers. This means that when looking for a Partner, we always ensure that their standard of service, ethos and ability to promptly innovate are aligned with ours. We are very happy to have found that in SYNLAB." For more information:
29.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | SYNLAB AG |
Moosacher Straße 88 | |
80809 Munich | |
Germany | |
Phone: | +49 1701183753 |
E-mail: | ir@synlab.com |
Internet: | www.synlab.com/ |
ISIN: | DE000A2TSL71 |
WKN: | A2TSL7 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1222522 |
End of News | DGAP News Service |
Interaktiv
Events im Fokus

Termine 2022
1./2. Juni 2022: Fachkonferenz Immobilien & Software | IT
13./14. Juli 2022: Fachkonferenz Beteiligungsgesellschaften & Consumer/Leisure
12./13. Oktober 2022: Fachkonferenz Finanzdienstleistungen/Technologie
Der AKTIONÄR News

26. Mai 08:00 LVMH-Konkurrent Kering: Große Gaming-Überraschung bei Gucci
26. Mai 08:15 Rekordhoch im Blick: Dieser AKTIONÄR-Tipp schwimmt auf der perfekten ...
26. Mai 08:32 Nach Brutal-Crash: Amazon-CEO in diesem wichtigen Punkt „sehr ...
26. Mai 10:00 Marinomed: Biotech-Geheimtipp mit starken Zahlen
26. Mai 10:48 Bavarian Nordic im Aufwind: Spanien will Affenpocken-Impfstoff ...
Aktuelle Research-Studie
Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index
25. Mai 2022